ABSTRACT -Background -There is evidence that shows that calcineurin inhibitors may be useful for the treatment of severe ulcerative colitis. However, evidence regarding the efficacy of tacrolimus for remission induction in this setting is scarce. Objective -To develop a systematic review on the existing evidence regarding the clinical efficacy of tacrolimus for the induction of remission in patients with moderate-to-severe ulcerative colitis. Methods -A literature search was undertaken from 1966 to August 2016 using MEDLINE, Embase, LILACS and the Cochrane Library. The following MeSH terms were used: "Inflammatory Bowel Diseases" or "Ulcerative Colitis" and "Calcineurin Inhibitors" or "Tacrolimus" or "FK506". Studies performed in adult ulcerative colitis patients that evaluated the clinical efficacy of tacrolimus for the induction of remission were considered for revision. A meta-analysis was performed with those included studies that were also placebo-controlled and randomized. Clinical response as well as clinical remission and mucosal healing were evaluated. Results -Overall, 755 references were identified, from which 22 studies were finally included. Only two of them were randomized, placebo-controlled trials. A total of 172 patients were evaluated. A significantly lower risk of failure in clinical response was found for tacrolimus versus placebo ]; moreover, a lower risk of failure in the induction of remission was also found versus placebo ]. Conclusion -Tacrolimus seems to be a valid therapeutic alternative for the induction of remission in patients with moderate-to-severe ulcerative colitis. HEADINGS -Inflammatory bowel diseases. Tacrolimus. Calcineurin inhibitors.
INTRODUCTION
Inflammatory Bowel Disease (IBD) is an immunological condition that carries a significant morbidity as well as mortality (1) . It has been classified as Crohn's Disease (CD) or Ulcerative Colitis (UC). Even though these entities share a common ground, they exhibit differences in terms of clinical presentation and therapeutic alternatives. During the last few years, there has been a significant development of scientific evidence showing the benefit of biological therapy -mainly anti-TNF α agents -in both scenarios (7) . Nevertheless, approximately 30% of patients with moderateto-severe disease, whether they are CD or UC patients, do not respond to anti-TNF α therapy (primary failure) (3) and a significant proportion of patients (13% to 25% per year of treatment) may develop resistance and hence loss of efficacy to this type of treatment (secondary failure) (27, 33) . This is why alternative therapeutic strategies are needed for these patients so that clinical conditions are improved and potentially serious complications can be avoided.
There is some evidence that show the efficacy of calcineurin inhibitors for the treatment of patients with severe UC (18) . Due to the effect that these drugs exert on calcineurin, they can inhibit the transcription of the Interleukin-2 gene -among others -which is necessary for the activation of T lympochytes (2) . As a consequence, although the quality of the available evidence is far from ideal, cyclosporine has been used in this clinical context; much less evidence is available in the CD scenario.
Efficacy of tacrolimus for induction of remission in patients with moderate-to-severe ulcerative colitis: a systematic review and meta-analysis
Bearing this in mind, a class-effect on moderate-to-severe UC could be inferred; consequently, the use of other calcineurin inhibitors such as tacrolimus has been proposed. Tacrolimus has the advantages of oral administration, a well-known safety profile and the previous experience of use in other clinical settings (31) . However, the evidence of the efficacy of its use in moderate-to-severe UC is scarce.
As a consequence, we sought to carry out a systematic review of the available evidence on this matter, with a meta-analysis considering randomized controlled trials.
METHODS
A literature search was carried out from 1966 to August 2016 using the following databases: MEDLINE, Embase, LILACS and The Cochrane Library. The search strategy included the following MeSH terms: "Inflammatory Bowel Disease" or "Ulcerative Colitis" and "Calcineurin Inhibitors" or "Tacrolimus" or "FK-506". Also, we reviewed the bibliographic references of the papers identified as potentially relevant. Additionally, we manually reviewed the abstracts of the Digestive Disease Week and United European Gastroenterology Week from 2010 to 2016.
The two authors performed bibliographic search in an independent manner. Potentially relevant abstracts were reviewed to check if they fulfilled inclusion criteria. These criteria were: a) studies that addressed the efficacy of tacrolimus in more than five UC patients; b) studies performed in adult population. For meta-analysis performance, studies which fulfilled the aforementioned criteria and were randomized controlled trials were included. PRISMA recommendations were followed for this purpose.
Authors' findings were then compared. If there was disagreement regarding the inclusion of a study, this would be discussed until consensus was reached. If data duplication was suspected, the authors of the studies would be contacted to exclude this situation.
The methodological quality of the included studies would be evaluated following the Evidence-Based Gastroenterology Sterring Group recommendations (29) . In addition, Jadas score was estimated for each study.
Outcome measures were: clinical response, clinical remission after induction treatment and, if available, mucosal healing rate.
Meta-analysis was performed using REVMAN software (Review Manager Version 5.1. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2011). Heterogeneity was estimated by means of I2 test and chi square test. If no significant heterogeneity was found, a fixed-effect model would be used for meta-analysis; otherwise, a random-effect model would be preferred. Outcome measures were described as Relative Risks (RR) with their corresponding 95% Confidence Interval (95%CI). Additionally, their corresponding Number Necessary to Treat (NNT) were calculated.
RESULTS
Overall, 755 potentially relevant citations were identified; 48 of them were furtherly chosen for analysis. Figure 1 shows the flow diagram which describes the reasons for citations exclusion. Finally, 22 studies (4) (5) (6) (9) (10) (11) (12) (13) (14) (15) (16) (17) (20) (21) (22) (23) (24) (25) 28, 30, 32, 33) that fulfilled eligibility criteria were included. Only two studies were randomized controlled trials (24, 25) (Ogata 2006 and Ogata 2012); these were included for meta-analysis. Table 1 describes the main features of the non-controlled studies that evaluated the efficacy of tacrolimus in patients with UC. The population included in these studies are rather similar -moderateto-severe UC patients which are steroid-dependent or steroidrefractory-but certain discrepancy was found in the way that clinical response and clinical remission were defined: some studies used Truelove Witts criteria, whereas others used Lichtiger score. Some minor differences in terms of follow up time were also found. It is worth mentioning that only one of these studies (14) (Ikeya 2015) considered mucosal healing as an outcome. The tacrolimus dosage was adjusted to obtain a serum level between 10 to 15 ng/ mL. Overall, 609 patients were included in non-controlled studies: in many of these cases, colectomy was delayed but not avoided. Only two studies (24, 25) (Ogata 2006 and Ogata 2012) were randomized controlled trials. The features of these trials are shown in Table 2 . Overall, 127 UC patients were included for meta-analysis. Table 3 shows the methodological analysis of these two trials. As witnessed in Figure 2 The most commonly reported severe adverse events were gastroenteritis and sepsis. When considering only the randomized controlled trials, there was not a significant increase in the risk of serious adverse events versus placebo [RR 3.38 (0.17-68.91)].
DISCUSSION
According to the results observed in our systematic review, tacrolimus therapy could be a valid alternative in the context of moderate-to-severe UC that have not responded to other treatments or who are regarded as cortico-dependent or refractory.
As mentioned before, evidence on the efficacy of calcineurin inhibitors derives mainly from the experience of cyclosporine as a rescue therapy in the setting of severe UC. In a pioneer study, Lichtiger et al. (18) showed that endovenous cyclosporine was useful to avoid colectomy in patients with severe UC flares after systemic steroid therapy failure. D'Haens et al. (8) concluded that cyclosporine is a valid alternative to intravenous steroids in severe flares. Additionally, controlled studies have shown that cyclosporine may be equivalent to Infliximab in this type of clinical scenario (18) . Nevertheless, it should be reminded that cyclosporine has a nonneglectable adverse event profile and there is much less evidence apart from its parenteral use.
Tacrolimus is a well-known calcineurin inhibitor that is widely used as immunosupresant therapy in the context of transplant or even for the treatment of autoinmmune conditions (31) . Tacrolimus has the advantage that it can be administered orally and that its serum concentration can be easily measured and adjusted to reach the adequate level in each case. The initial experience in UC patients was originated in referral centers from Japan, and then it was adopted by some centers in Europe. According to what is witnessed in uncontrolled studies, tacrolimus shows a high proportion of clinical response in the short-term, with a low NNT; however, when clinical remission is considered, such proportion is lower and more variable.
It is worth mentioning, according to what is observed from uncontrolled studies, the relatively high proportion of patients who would eventually require colectomy in spite of receiving tacrolimus (4, 5, 10, 13, 28, 32) (Fellermann 2002 , Hogenauer 2003 , Baumgart 2006 , Benson 2007 , Yamamoto 2008 , Schmidt 2013 . As a consequence, it would seem like tacrolimus could delay the need for colectomy in a selected group of patients -those moderate-to-severe UC patients with prior failure to other therapeutic alternatives. It should also be mentioned that no study has considered tacrolimus therapy in patients with less severe disease.
There is a scarcity of high-quality trials to know the real impact of tacrolimus in the management of UC. As a matter of fact, as shown by this review, there has only been published two controlled trials (24, 25) (Ogata 2006 and Ogata 2012) , with a relatively low number of patients and a rather short follow up time. One strength of these two trials is that mucosal healing was included as an outcome, which is known to be a relevant prognostic factor and a therapeutic target, particularly when it comes to UC (26) . It is also worth mentioning that all studies assessed the efficacy of oral tacrolimus for the continued treatment of UC patients.
Evidence on the efficacy of calcineurin inhibitors in the setting of CD is more scarce: there are only a few controlled trials, mainly on patients with perianal disease, and few cohort studies (19) . Nevertheless, the relatively few alternatives in severe CD may turn tacrolimus into a valid therapeutic option, regardless of the few scientific evidence available.
Some limitations should be mentioned. First of all, there were few studies included for meta-analysis, so the conclusions should be cautiously interpreted. We decided not to perform meta-analysis with observational uncontrolled studies, because this represents a high risk for relevant biases, which could in turn produce a distortion in the conclusions derived from higherquality studies. Last but not least, it is worth mentioning that most observational studies were retrospective, with the logical limitations that this implicate.
In conclusion, tacrolimus seems to show in both uncontrolled studies as well as in placebo controlled trials, a significant efficacy to induce clinical response and remission in moderate-to-severe UC. However, more evidence is undoubtfully needed to fully estimate the magnitude of its benefit.
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